Clinical Trial Update: Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease [Phase 3]

View source ↗

Summary

Results from a Phase 3 trial evaluating the lumacaftor/ivacaftor combination in cystic fibrosis patients aged 12 and older with advanced lung disease have been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ORKAMBI (lumacaftor and ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis, Advanced Lung Disease | Phase 3 | Status: COMPLETED | Results posted: 2017-11-01